# Zobair M. Younossi

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/zobair-m-younossi/

## Facts

| Field | Value |
| --- | --- |
| Citations | 133,921 |
| Field | Liver Disease Diagnosis and Treatment |
| h-index | 142 |
| i10-index | 645 |
| Last Known Institution | Inova Health System |
| OpenAlex ID | https://openalex.org/A5080386622 |
| ORCID iD | https://orcid.org/0000-0001-9313-577X |
| Works | 1,495 |

## Researcher papers

- [Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention](https://scholariq.org/papers/global-burden-of-nafld-and-nash-trends-predictions-risk-factors-and-prevention/)
- [MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease](https://scholariq.org/papers/mafld-a-consensus-driven-proposed-nomenclature-for-metabolic-associated-fatty/)
- [A multisociety Delphi consensus statement on new fatty liver disease nomenclature](https://scholariq.org/papers/a-multisociety-delphi-consensus-statement-on-new-fatty-liver-disease/)
- [A multisociety Delphi consensus statement on new fatty liver disease nomenclature](https://scholariq.org/papers/a-multisociety-delphi-consensus-statement-on-new-fatty-liver-disease-3/)
- [Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis](https://scholariq.org/papers/global-perspectives-on-nonalcoholic-fatty-liver-disease-and-nonalcoholic/)
- [A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis](https://scholariq.org/papers/a-phase-3-randomized-controlled-trial-of-resmetirom-in-nash-with-liver-fibrosis/)
- [Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial](https://scholariq.org/papers/obeticholic-acid-for-the-treatment-of-non-alcoholic-steatohepatitis-interim/)
- [Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis](https://scholariq.org/papers/association-between-fibrosis-stage-and-outcomes-of-patients-with-nonalcoholic/)
- [A multisociety Delphi consensus statement on new fatty liver disease nomenclature](https://scholariq.org/papers/a-multisociety-delphi-consensus-statement-on-new-fatty-liver-disease-2/)
- [Advancing the global public health agenda for NAFLD: a consensus statement](https://scholariq.org/papers/advancing-the-global-public-health-agenda-for-nafld-a-consensus-statement/)
- [Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials](https://scholariq.org/papers/selonsertib-for-patients-with-bridging-fibrosis-or-compensated-cirrhosis-due-to/)
- [4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2025](https://scholariq.org/papers/4-comprehensive-medical-evaluation-and-assessment-of-comorbidities-standards-of/)

## Researcher topics

- [Liver Disease Diagnosis and Treatment](https://scholariq.org/topics/liver-disease-diagnosis-and-treatment/)
- [Hepatitis C virus research](https://scholariq.org/topics/hepatitis-c-virus-research/)
- [Liver Disease and Transplantation](https://scholariq.org/topics/liver-disease-and-transplantation/)
- [Liver Diseases and Immunity](https://scholariq.org/topics/liver-diseases-and-immunity/)
- [Diet, Metabolism, and Disease](https://scholariq.org/topics/diet-metabolism-and-disease/)

## Researcher university

- [Inova Health System](https://scholariq.org/institutions/inova-health-system/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.